Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (372)
NICE advice (1)
Quality standard (10)
Guidance programme
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (10)
Medical technologies guidance (11)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (301)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 201 to 250 of 383
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Mental health guidelines
NICE guideline
TBC
Mirikizumab for treating moderately to severely active Crohn's disease [ID6244]
Technology appraisal guidance
13 November 2024
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]
Technology appraisal guidance
TBC
Molnupiravir for treating COVID 19 [ID6340]
Technology appraisal guidance
29 January 2025
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
Technology appraisal guidance
TBC
Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]
Technology appraisal guidance
TBC
Nemolizumab for treating moderate to severe atopic dermatitis in people aged 12 and over or prurigo nodularis in adults ID6221
Technology appraisal guidance
TBC
Nemolizumab for treating prurigo nodularis in adults ID6451
Technology appraisal guidance
TBC
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]
Technology appraisal guidance
TBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
Technology appraisal guidance
28 June 2017
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]
Technology appraisal guidance
TBC
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]
Technology appraisal guidance
TBC
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
Technology appraisal guidance
17 July 2024
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]
Technology appraisal guidance
TBC
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
Technology appraisal guidance
TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]
Technology appraisal guidance
TBC
Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]
Technology appraisal guidance
TBC
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]
Technology appraisal guidance
TBC
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629
Technology appraisal guidance
TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Technology appraisal guidance
TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]
Technology appraisal guidance
TBC
Non-invasive skin closure devices for surgical incisions (MT775)
Medical technologies guidance
TBC
Novel home-testing devices for diagnosing obstructive sleep apnoea/hypopnoea syndrome
Diagnostics guidance
11 September 2024
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]
Technology appraisal guidance
4 December 2024
NY-ESO-1 T-cells for treating synovial sarcoma ID1286
Technology appraisal guidance
TBC
Obesity: clinical assessment and management (QS update)
Quality standard
TBC
Obesity: prevention and lifestyle management (QS update)
Quality standard
TBC
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]
Technology appraisal guidance
TBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]
Technology appraisal guidance
TBC
Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]
Technology appraisal guidance
TBC
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]
Technology appraisal guidance
25 September 2024
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]
Technology appraisal guidance
TBC
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]
Highly specialised technology
TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]
Technology appraisal guidance
TBC
One-piece closed bags for adults with a colostomy: Late Stage Assessment
Health technology evaluation
TBC
ONS-5010 for treating wet age-related macular degeneration ID6320
Technology appraisal guidance
TBC
Optical Coherence Tomography to guide percutaneous coronary intervention
Interventional procedures guidance
TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]
Technology appraisal guidance
TBC
OrganOx metra for liver transplant [ID5116]
Technology appraisal guidance
TBC
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]
Technology appraisal guidance
14 August 2024
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]
Technology appraisal guidance
TBC
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)
NICE guideline
TBC
Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]
Technology appraisal guidance
TBC
Ovarian cancer QS update
Quality standard
5 February 2025
Overweight and obesity management
NICE guideline
TBC
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]
Technology appraisal guidance
TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]
Technology appraisal guidance
TBC
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]
Technology appraisal guidance
TBC
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]
Highly specialised technology
TBC
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]
Highly specialised technology
TBC
Previous page
1
…
3
4
Current page
5
6
7
8
Page
5
of
8
Next page
Results per page
10
25
50
All
Back to top